Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of BMS-986165 in Moderate to Severe Ulcerative Colitis
2018-004694-27Phase 2Unknown
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing BMS-986165 with Placebo (2 arms). Primary endpoint: Clinical remission (modified Mayo Score). Status: unknown.
02
Drugs
deucravacitinib
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2018-004694-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-004694-27.